TrialThe Lancet. Infectious diseases2021

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial.

Raches Ella et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.